ANI Pharmaceuticals
ANIP
81 hedge funds and large institutions have $156M invested in ANI Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 30 increasing their positions, 19 reducing their positions, and 12 closing their positions.
117% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 12
58% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 19
32% more capital invested
Capital invested by funds: $118M → $156M (+$38M)
21% more funds holding
Funds holding: 67 → 81 (+14)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$7.39M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$5.31M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$4.29M |
| 4 |
Renaissance Technologies
New York
|
+$3.69M |
| 5 |
CCM
Consonance Capital Management
New York
|
+$3.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$6.31M |
| 2 |
Millennium Management
New York
|
-$5.57M |
| 3 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$3.14M |
| 4 |
MOACM
Mutual of America Capital Management
New York
|
-$1.72M |
| 5 |
PA
Perceptive Advisors
New York
|
-$1.41M |
ANIP Hedge Fund Activity: Q2 2014 in Review
81 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q2 2014, worth a combined $156M — up 32% from $118M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ANIP positions and 12 closed out — a net gain of 14 holders — while 30 added to existing stakes and 19 trimmed.
The largest buyer was Deerfield Management, adding an estimated $7.39M. The largest seller was Kennedy Capital Management, exiting entirely with an estimated $6.31M sold.
- 81 institutional investors held ANI Pharmaceuticals (ANIP) as of Q2 2014, up from 67 in Q1 2014.
- Funds reported $156M of ANI Pharmaceuticals stock for Q2 2014, up 32% quarter-over-quarter.
- 26 funds opened new ANI Pharmaceuticals positions in Q2 2014 and 12 closed out, a net change of +14 holders.
- The largest ANI Pharmaceuticals buyer in Q2 2014 was Deerfield Management, an estimated $7.39M added.
- The largest ANI Pharmaceuticals seller in Q2 2014 was Kennedy Capital Management, an estimated $6.31M sold.
Based on aggregated 13F filings for Q2 2014.